Sahil Mishra

Medicinal chemist with strong expertise in synthetic organic chemistry, structure-based drug design, and lead optimization for infectious diseases. Currently a Postdoctoral Research Fellow focused on designing, synthesizing, and biologically evaluating novel isoniazid derivatives targeting the InhA enzyme of Mycobacterium tuberculosis. Previously worked as a Research Associate at Pharmaffiliates CRO, specializing in the synthesis of API impurities and reference standards under strict pharmacopeial guidelines. Proficient in multi-step synthesis, SAR analysis, molecular docking, ADME/Tox prediction, and advanced analytical techniques (NMR, LC-MS, HPLC, IR). Experienced in collaborative research, GLP compliance, and scientific communication through publications and presentations. Driven Postdoctoral Research Associate in [Area of expertise] with experience at [Type] institution. Detail-oriented and systematic with strong desire to develop abilities useful in [Type] employment.

• Qualified CSIR-UGC NET exam with the all India Rank of 41
• Qualified DST-JRF interview.
• Qualified CSIR-RA (Research Associate) interview.
• Mentorship, Guru Nanak Dev University, Amritsar, Punjab, India, Aug 2015-Nov 2019
• Designed an original research project that was performed by postgraduate students. Advised and taught students to correct techniques and skills to complete the project.
• Gave a talk and presented a poster on Anti-Tb drug discovery at Gordon Research Seminar held in Barcelona, Spain, from 19-20 July 2025.

• Gobind Kumar, Archna, Sahil Mishra, Safiyah Ghumran, Neha Manhas, Rupesh Kumar, Parvesh Singh, and Gaurav Bhargava. Recent Advances in Catalyst-mediated [6+4] Cycloaddition Reactions: A concise review (EJOC 2025, https://doi.org/10.1002/ejoc.202500349)
• Gobind Kumar, Pule Seboletswe, Sahil Mishra, Françoise Roquet-Banères, Maëlle Foubert, Laurent Kremer, Gaurav Bhargava, Parvesh Singh. Isoniazid-Dihydropyrimidinone Molecular Hybrids: Design, Synthesis, Antitubercular Activity, and Cytotoxicity Investigations with Computational Validation, ChemMedChem 2025, 20, e202400949.
• Sahil Mishra, Gobind Kumar, Parvesh Singh. Isoniazid Hybrids as Potential Antitubercular Agents. ChemistrySelect 2024 (Review Article).
• Sanjeev Dhawan, Gobind Kumar, Sahil Mishra, Parvesh Singh. Coumarin-Tethered-1,2,3-Triazoles: Synthesis, Characterization, Antimicrobial Evaluation, and DFT Studies, ChemistrySelect 2024.
• Kalpana Pawar, Anshuman Yadav, Parteek Prasher, Sahil Mishra, Balwinder Singh, Palwinder Singh and Sneha Sudha Komath. Identification of an indole-triazole-amino acid conjugate as high effective antifungal agent. Med. Chem. Comm. 2015, 6, 1352-1359.
• Sahil Mishra, Manpreet Kaur, Subhash Chander, Sankaranarayanan Murugesan, Lovedeep Nim, D.S. Arora, Palwinder Singh. Rational modification of a lead molecule: Improving the antifungal activity of indole triazole-amino acid conjugates, Eur. J. Med. Chem. 2018, 155, 658-669.
• B Kaur, Sahil Mishra, R Kaur, S Kalotra, P Singh. Rationally designed TNF-α inhibitors: Identification of promising cytotoxic agents, Bioorg. Med. Chem. Lett. 2021, 41, 127982.
• Rahul Kumar, Sahil Mishra, Sushil Kumar Maurya. Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses, RSC Med. Chem. 2021, 12 (3), 306-320 (Review Article, Inside Cover image).
• Shaveta, Sahil Mishra, Palwinder Singh. Hybrid Molecules: The privileged scaffolds for various pharmaceuticals, Eur. J. Med. Chem. 2016, 124, 500-53 (Review Article).

• Post-doctoral Research Associate
• University of Kwazulu-Natal University, Durban, South Africa: Jan 2024-Present
• Molecular modelling based design and synthesis of Isoniazid based anti-tuberculosis agents and their biochemical studies.

Languages: English, Hindi

Hobbies: Gyming, Trekking

• Invited to deliver an oral presentation and presented research posters at the Gordon Research Seminars (GRS) and Gordon Research Conference (GRC) on Tuberculosis Drug Discovery, held in Barcelona, Spain in July 2025.
• Presented a Poster at the In-silico drug design conference organized by Schrodinger at JNU, New Delhi.
• Delivered an oral presentation at the Computational and Systems Biology Conference held at Durban University of Technology.